TrialCancer chemotherapy and pharmacology2016

A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.

Soushi Ibata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.